Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 5,512 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Hyperuricemia
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Gout
Interventions: Rilonacept, Placebo (for Rilonacept); Biological · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 34
States / cities: San Diego, California • Santa Maria, California • Whittier, California + 30 more

Conditions: Ulcerative Colitis
Interventions: Telotristat Etiprate, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Little Rock, Arkansas • Anaheim, California • Santa Monica, California + 8 more

Conditions: Type 2 Diabetes
Interventions: CAT 1004, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Interventions: Soquelitinib, Placebo; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: South San Francisco, California

Conditions: Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions: Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel; Drug
Lead sponsor: bioRASI, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more

Conditions: Psoriasis
Interventions: JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more

Conditions: Asthma
Interventions: Placebo ELLIPTA inhaler, Questionnaire; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more

Conditions: Essential Hypertension
Interventions: Allopurinol, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Neoplasms
Interventions: alpelisib, placebo, nab-paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Baton Rouge, Louisiana • Rochester, Minnesota + 2 more

Conditions: Lupus Nephritis
Interventions: Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Tinnitus
Interventions: Modafinil, Placebo; Drug · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 20 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Alcoholism
Interventions: Acamprosate, Naltrexone, Placebo; Drug
Lead sponsor: The Scripps Research Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Type 2 Diabetes
Interventions: Insulin glargine injection, metformin, Placebo pill; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Urge Urinary Incontinence, Urinary Frequency
Interventions: Oxybutynin, Placebo; Drug
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 55
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Placebo, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 15 more

Conditions: Cirrhosis, Liver
Interventions: Ceftriaxone, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congenital Heart Disease (CHD)
Interventions: 2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 1 Month to 3 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
Interventions: VT30; Drug
Lead sponsor: Venthera, Inc., a BridgeBio company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Osteoarthritis Knee Pain
Interventions: Duloxetine (DLX), Placebo (PLA); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years and older
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Montgomery, Alabama • Phoenix, Arizona • Spring Valley, California + 7 more

Conditions: Heart Failure
Interventions: GSK2798745, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Actinic Keratosis
Interventions: LEO 43204, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Phoenix, Arizona • Lomita, California • San Diego, California + 9 more

Conditions: Pseudohypoparathyroidism, Albright Hereditary Osteodystrophy
Interventions: Theophylline, Placebos; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 13 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV-1 Infection
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 31
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more

Search by objective public record fields.

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma

Uric Acid in Essential Hypertension in Children

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

Use of Modafinil in the Treatment of Tinnitus

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Prophylactic Antibiotics in Admitted Cirrhotics

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations

A Study of Duloxetine in Patients With Osteoarthritis Knee Pain

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Theophylline Treatment for Pseudohypoparathyroidism

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults